Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.

Iwai K, Yaguchi M, Nishimura K, Yamamoto Y, Tamura T, Nakata D, Dairiki R, Kawakita Y, Mizojiri R, Ito Y, Asano M, Maezaki H, Nakayama Y, Kaishima M, Hayashi K, Teratani M, Miyakawa S, Iwatani M, Miyamoto M, Klein MG, Lane W, Snell G, Tjhen R, He X, Pulukuri S, Nomura T.

EMBO Mol Med. 2018 May 16. pii: e8289. doi: 10.15252/emmm.201708289. [Epub ahead of print]

2.

Discovery of spiro[indole-3,2'-pyrrolidin]-2(1H)-one based inhibitors targeting Brr2, a core component of the U5 snRNP.

Ito M, Iwatani M, Yamamoto T, Tanaka T, Kawamoto T, Morishita D, Nakanishi A, Maezaki H.

Bioorg Med Chem. 2017 Sep 1;25(17):4753-4767. doi: 10.1016/j.bmc.2017.07.017. Epub 2017 Jul 13.

PMID:
28751196
3.

Discovery of selective ATP-competitive eIF4A3 inhibitors.

Ito M, Iwatani M, Kamada Y, Sogabe S, Nakao S, Tanaka T, Kawamoto T, Aparicio S, Nakanishi A, Imaeda Y.

Bioorg Med Chem. 2017 Apr 1;25(7):2200-2209. doi: 10.1016/j.bmc.2017.02.035. Epub 2017 Feb 20.

PMID:
28283335
4.

CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.

Funnell T, Tasaki S, Oloumi A, Araki S, Kong E, Yap D, Nakayama Y, Hughes CS, Cheng SG, Tozaki H, Iwatani M, Sasaki S, Ohashi T, Miyazaki T, Morishita N, Morishita D, Ogasawara-Shimizu M, Ohori M, Nakao S, Karashima M, Sano M, Murai A, Nomura T, Uchiyama N, Kawamoto T, Hara R, Nakanishi O, Shumansky K, Rosner J, Wan A, McKinney S, Morin GB, Nakanishi A, Shah S, Toyoshiba H, Aparicio S.

Nat Commun. 2017 Feb 23;8(1):7. doi: 10.1038/s41467-016-0008-7.

5.

Prolyl-tRNA synthetase inhibition promotes cell death in SK-MEL-2 cells through GCN2-ATF4 pathway activation.

Arita T, Morimoto M, Yamamoto Y, Miyashita H, Kitazawa S, Hirayama T, Sakamoto S, Miyamoto K, Adachi R, Iwatani M, Hara T.

Biochem Biophys Res Commun. 2017 Jul 8;488(4):648-654. doi: 10.1016/j.bbrc.2017.01.045. Epub 2017 Jan 11.

PMID:
28087278
6.

A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.

Ishikawa Y, Gamo K, Yabuki M, Takagi S, Toyoshima K, Nakayama K, Nakayama A, Morimoto M, Miyashita H, Dairiki R, Hikichi Y, Tomita N, Tomita D, Imamura S, Iwatani M, Kamada Y, Matsumoto S, Hara R, Nomura T, Tsuchida K, Nakamura K.

Mol Cancer Ther. 2017 Feb;16(2):273-284. doi: 10.1158/1535-7163.MCT-16-0471. Epub 2016 Nov 30.

7.

Mechanism of sonochemical reduction of permanganate to manganese dioxide in aqueous alcohol solutions: Reactivities of reducing species formed by alcohol sonolysis.

Okitsu K, Iwatani M, Okano K, Uddin MH, Nishimura R.

Ultrason Sonochem. 2016 Jul;31:456-62. doi: 10.1016/j.ultsonch.2016.01.005. Epub 2016 Jan 19.

PMID:
26964972
8.

Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing.

Araki S, Dairiki R, Nakayama Y, Murai A, Miyashita R, Iwatani M, Nomura T, Nakanishi O.

PLoS One. 2015 Jan 12;10(1):e0116929. doi: 10.1371/journal.pone.0116929. eCollection 2015.

9.

In vitro characterization of the RS motif in N-terminal head domain of goldfish germinal vesicle lamin B3 necessary for phosphorylation of the p34cdc2 target serine by SRPK1.

Yamaguchi A, Iwatani M, Ogawa M, Kitano H, Matsuyama M.

FEBS Open Bio. 2013 Mar 29;3:165-76. doi: 10.1016/j.fob.2013.03.003. Print 2013.

10.

Structure-based discovery of cellular-active allosteric inhibitors of FAK.

Tomita N, Hayashi Y, Suzuki S, Oomori Y, Aramaki Y, Matsushita Y, Iwatani M, Iwata H, Okabe A, Awazu Y, Isono O, Skene RJ, Hosfield DJ, Miki H, Kawamoto T, Hori A, Baba A.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1779-85. doi: 10.1016/j.bmcl.2013.01.047. Epub 2013 Jan 26.

PMID:
23414845
11.

Discovery and characterization of novel allosteric FAK inhibitors.

Iwatani M, Iwata H, Okabe A, Skene RJ, Tomita N, Hayashi Y, Aramaki Y, Hosfield DJ, Hori A, Baba A, Miki H.

Eur J Med Chem. 2013 Mar;61:49-60. doi: 10.1016/j.ejmech.2012.06.035. Epub 2012 Jun 26.

PMID:
22819505
12.

Genome-wide DNA methylation profile of tissue-dependent and differentially methylated regions (T-DMRs) residing in mouse pluripotent stem cells.

Sato S, Yagi S, Arai Y, Hirabayashi K, Hattori N, Iwatani M, Okita K, Ohgane J, Tanaka S, Wakayama T, Yamanaka S, Shiota K.

Genes Cells. 2010 Jun;15(6):607-18. doi: 10.1111/j.1365-2443.2010.01404.x. Epub 2010 May 13.

13.

Resistance to 5-aza-2'-deoxycytidine in genic regions compared to non-genic repetitive sequences.

Lim HW, Iwatani M, Hattori N, Tanaka S, Yagi S, Shiota K.

J Reprod Dev. 2010 Feb;56(1):86-93. Epub 2009 Dec 9.

14.

Radiographic repair in three Japanese patients with rheumatoid arthritis treated with bucillamine.

Nanke Y, Iwatani M, Kobashigawa T, Yago T, Yamanaka H, Kotake S.

Mod Rheumatol. 2009;19(6):681-6. doi: 10.1007/s10165-009-0209-6. Epub 2009 Aug 27.

PMID:
19711150
15.

Establishment of trophoblast stem cell lines from somatic cell nuclear-transferred embryos.

Oda M, Tanaka S, Yamazaki Y, Ohta H, Iwatani M, Suzuki M, Ohgane J, Hattori N, Yanagimachi R, Wakayama T, Shiota K.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16293-7. doi: 10.1073/pnas.0908009106. Epub 2009 Aug 24.

16.

Sonochemical reduction of permanganate to manganese dioxide: the effects of H2O2 formed in the sonolysis of water on the rates of reduction.

Okitsu K, Iwatani M, Nanzai B, Nishimura R, Maeda Y.

Ultrason Sonochem. 2009 Mar;16(3):387-91. doi: 10.1016/j.ultsonch.2008.10.009. Epub 2008 Oct 29.

PMID:
19038568
17.

Genome-wide and locus-specific DNA hypomethylation in G9a deficient mouse embryonic stem cells.

Ikegami K, Iwatani M, Suzuki M, Tachibana M, Shinkai Y, Tanaka S, Greally JM, Yagi S, Hattori N, Shiota K.

Genes Cells. 2007 Jan;12(1):1-11.

18.

Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA.

Iwatani M, Inoue E, Nakamura T, Nakajima A, Hara M, Tomatsu T, Kamatani N, Yamanaka H.

Mod Rheumatol. 2006;16(6):376-80. Epub 2006 Dec 20.

PMID:
17165000
19.

Dimethyl sulfoxide has an impact on epigenetic profile in mouse embryoid body.

Iwatani M, Ikegami K, Kremenska Y, Hattori N, Tanaka S, Yagi S, Shiota K.

Stem Cells. 2006 Nov;24(11):2549-56. Epub 2006 Jul 13.

20.

[Diet therapy for management of hyperuricemia and gout].

Iwatani M.

Nihon Rinsho. 2003 Jan;61 Suppl 1:184-92. Review. Japanese. No abstract available.

PMID:
12629715
21.

[Uric acid metabolism and insulin resistance in type 2 diabetes].

Wasada T, Iwatani M.

Nihon Rinsho. 2002 Aug;60 Suppl 8:167-72. Review. Japanese. No abstract available.

PMID:
12355741
22.

Influence of moderate drinking on purine and carbohydrate metabolism.

Nishioka K, Sumida T, Iwatani M, Kusumoto A, Ishikura Y, Hatanaka H, Yomo H, Kohda H, Ashikari T, Shibano Y, Suwa Y.

Alcohol Clin Exp Res. 2002 Aug;26(8 Suppl):20S-25S.

PMID:
12198370
23.

Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.

Iwatani M, Wasada T, Katsumori K, Watanabe-Takahashi C, Kamatani N, Iwamoto Y.

Diabetologia. 2000 Jun;43(6):814-5. No abstract available.

PMID:
10907128
24.

[Insulin sensitizer and urate metabolism].

Iwatani M, Wasada T, Iwamoto Y, Kamatani N.

Nihon Rinsho. 2000 Feb;58(2):430-4. Review. Japanese.

PMID:
10707571
25.

Tarsal tunnel syndrome caused by tophaceous gout a case report.

Wakabayashi T, Irie K, Yamanaka H, Iwatani M, Inoue K.

J Clin Rheumatol. 1998 Jun;4(3):151-5. No abstract available.

PMID:
19078277
26.

[Altered uric acid metabolism in diabetes mellitus].

Wasada T, Iwatani M.

Nihon Rinsho. 1997 Oct;55 Suppl:637-40. Review. Japanese. No abstract available.

PMID:
9392174
27.

[Hyperuricemia and insulin resistance].

Wasada T, Katsumori K, Saeki A, Iwatani M.

Nihon Rinsho. 1996 Dec;54(12):3293-6. Review. Japanese.

PMID:
8976108
28.

[Hyperuricemia and atherosclerosis].

Nishioka K, Iwatani M.

Nihon Rinsho. 1993 Aug;51(8):2177-81. Japanese.

PMID:
8411689
29.

[The prognosis of gout and hyperuricemia--the effect of the treatment on prognosis].

Iwatani M, Nishioka K.

Nihon Rinsho. 1991 May;49(5):1124-30. Review. Japanese. No abstract available.

PMID:
2067104
30.

Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion.

Ohashi S, Iwatani M, Hyakuna Y, Morioka Y.

Arzneimittelforschung. 1985;35(7A):1203-8.

PMID:
4074436
31.

Plasma amino acid levels in hyperosmolar nonketotic diabetic coma.

Tasaka Y, Iwatani M, Inoue S, Marumo K, Hirata Y.

Horm Metab Res. 1983;15(2):59-61.

PMID:
6826141
32.

[Evaluation of the skin blood flow rate by heat flow analysis].

Iwatani M.

Iyodenshi To Seitai Kogaku. 1982 Aug;20(4):249-55. Japanese. No abstract available.

PMID:
7154405
33.

[Proceedings: Pancreatic glucagon in the blood of diabetic patients].

Tasaka Y, Sekine M, Yokosuka T, Iwatani M, Shizume K.

Nihon Naibunpi Gakkai Zasshi. 1974 Feb 20;50(2):247. Japanese. No abstract available.

PMID:
4476373
34.

[Round table conference. The life of a dentist].

Iwatani M, Watanabe M, Yamamoto S, Kidokoro M.

Nihon Shika Ishikai Zasshi. 1966 Oct;19(7):571-82. Japanese. No abstract available.

PMID:
5226495

Supplemental Content

Loading ...
Support Center